Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Float Short %

0.32

Margin Of Safety %

-5

Put/Call OI Ratio

1.87

EPS Next Q Diff

-0.17

EPS Last/This Y

3.01

EPS This/Next Y

0.3

Price

144.99

Target Price

140.77

Analyst Recom

2.55

Performance Q

10.4

Relative Volume

0.68

Beta

0.49

Ticker: NVS




18 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-12-26NVS139.171.690.1769282
2025-12-29NVS139.291.682.4069565
2025-12-30NVS138.761.680.4370162
2025-12-31NVS137.861.680.7070538
2026-01-02NVS138.511.688.4970722
2026-01-05NVS137.921.723.5972422
2026-01-06NVS142.31.721.0272610
2026-01-07NVS141.931.730.2273100
2026-01-08NVS141.521.680.9374384
2026-01-09NVS141.551.680.7974664
2026-01-12NVS141.871.680.5874794
2026-01-13NVS141.651.670.0575575
2026-01-14NVS146.21.730.7774600
2026-01-15NVS143.211.720.5475405
2026-01-16NVS144.361.720.2575685
2026-01-20NVS143.521.990.6342058
2026-01-21NVS145.151.890.7243785
2026-01-22NVS1451.870.3444746
DateSymbolLatestP/C OIP/C VolTotal OI
18 items Current Page1 of 1




18 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-12-26NVS139.20-2.72813.58.93
2025-12-29NVS139.25-2.72922.68.93
2025-12-30NVS138.73-2.72874.08.93
2025-12-31NVS137.91-2.72755.48.93
2026-01-02NVS138.55-2.72909.38.93
2026-01-05NVS137.95-2.72888.98.93
2026-01-06NVS142.31-2.73600.68.93
2026-01-07NVS141.93-2.73004.68.93
2026-01-08NVS141.52-2.72686.08.93
2026-01-09NVS141.49-2.72703.38.93
2026-01-12NVS141.87-2.72743.38.93
2026-01-13NVS141.60-2.72794.68.93
2026-01-14NVS146.16-2.73331.88.93
2026-01-15NVS143.17-2.72627.28.93
2026-01-16NVS144.34-2.73006.48.93
2026-01-20NVS143.520.52803.28.93
2026-01-21NVS145.140.53105.38.93
2026-01-22NVS144.990.52875.38.93
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
18 items Current Page1 of 1




18 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-12-26NVS0.00-0.210.29
2025-12-29NVS0.00-0.330.29
2025-12-30NVS0.00-0.330.29
2025-12-31NVS0.00-0.330.29
2026-01-02NVS0.00-0.330.29
2026-01-05NVS0.00-0.280.29
2026-01-06NVS0.00-0.280.29
2026-01-07NVS0.00-0.280.29
2026-01-08NVS0.00-0.280.29
2026-01-09NVS0.00-0.280.29
2026-01-12NVS0.00-0.270.29
2026-01-13NVS0.00-0.270.32
2026-01-14NVS0.00-0.270.32
2026-01-15NVS0.00-0.270.32
2026-01-16NVS0.00-0.270.32
2026-01-20NVS0.00-0.240.32
2026-01-21NVS0.00-0.240.32
2026-01-22NVS0.00-0.240.32
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
18 items Current Page1 of 1

Last Quarter Act. EPS

2.25

Avg. EPS Est. Current Quarter

1.93

Avg. EPS Est. Next Quarter

2.08

Insider Transactions

Institutional Transactions

-0.24

Beta

0.49

Average Sales Estimate Current Quarter

13810

Average Sales Estimate Next Quarter

13723

Fair Value

137.79

Quality Score

96

Growth Score

85

Sentiment Score

84

Actual DrawDown %

0.9

Max Drawdown 5-Year %

-20.4

Target Price

140.77

P/E

19.77

Forward P/E

15.88

PEG

1.96

P/S

5.05

P/B

6.28

P/Free Cash Flow

13.98

EPS

7.33

Average EPS Est. Cur. Y​

8.93

EPS Next Y. (Est.)

9.23

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

26.5

Relative Volume

0.68

Return on Equity vs Sector %

5.2

Return on Equity vs Industry %

-4.3

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

2875.3
Novartis AG
Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 75883
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
stock quote shares NVS – Novartis AG Stock Price stock today
news today NVS – Novartis AG stock forecast ,stock prediction 2023 2024 2025
marketwatch NVS – Novartis AG yahoo finance google finance
stock history NVS – Novartis AG invest stock market
stock prices NVS premarket after hours
ticker NVS fair value insiders trading